Accesswire
18 Mar 2026, 13:00 UTC · 27w ago
Verdict
Headline takes no side. We score JAGX +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 74% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Jaguar Health may apply for FDA Breakthrough Therapy designation for crofelemer in MVID treatment in the coming months.
More positive than 93% of claims this week
The FDA has supported a protocol amendment allowing Napo Pharmaceuticals to initiate a single-blind extension phase for its MVID clinical trial.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
Approximately 30% of participating MVID patients have completed the initial double-blind treatment phase.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 74% of ticker scores this week
FDA support for a clinical trial extension and the potential for Breakthrough Therapy designation are positive regulatory milestones.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
−97.2%
Price is moving against the score
$7.06 vs $252.90 close before publication (Mar 17) · not market-adjusted
JAGX chart →
